SNPX Insider Trading Activity and SEC Form 4 Filings
SNPX insider trading summary
No open-market insider purchases or sales of Synaptogenix, Inc. (SNPX) have been reported on SEC Form 4 in the past 12 months.
Latest SNPX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 16, 2022 | Robert Weinstein | Chief Financial Officer | Sell | $32K (27,000 @ $1.17) |
| Dec 16, 2022 | Alan J Tuchman | Chief Executive Officer | Sell | $32K (27,000 @ $1.17) |
| Dec 16, 2022 | Joshua Silverman | Director | Sell | $22K (19,012 @ $1.17) |
| Dec 16, 2022 | Daniel L. Alkon | President and CSO | Sell | $23K (19,688 @ $1.17) |
| Dec 16, 2022 | William S. Singer | Director | Sell | $32K (27,000 @ $1.17) |
| Dec 16, 2022 | Bruce Bernstein | Director | Sell | $26K (22,500 @ $1.17) |
| Dec 16, 2022 | Jonathan Schechter | Director | Sell | $24K (20,250 @ $1.17) |
| Jun 14, 2021 | Joshua Silverman | Director | Buy | $83K (10,000 @ $8.30) |
| Jun 14, 2021 | Daniel L. Alkon | Chief Scientific Officer | Buy | $83K (10,000 @ $8.26) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.